Alzheimer disease (AD), an age-related neurodegenerative disorder with progressive loss of memory and deterioration of comprehensive cognition, is characterized by extracellular senile plaques of aggregated β-amyloid (Aβ), and intracellular neurofibrillary tangles that contain hyperphosphorylated tau protein. Recent studies showed that melatonin, an indoleamine secreted by the pineal gland, may play an important role in aging and AD as an antioxidant and neuroprotector. Melatonin decreases during aging and patients with AD have a more profound reduction in this hormone. Data from clinical trials indicate that melatonin supplementation improves sleep, ameliorates sundowning, and slows down the progression of cognitive impairment in Alzheimer's patients. Melatonin efficiently protects neuronal cells from Aβ-mediated toxicity via antioxidant and anti-amyloid properties: it not only inhibits Aβ generation, but also arrests the formation of amyloid fibrils by a structure-dependent interaction with Aβ. Our recent studies have demonstrated that melatonin efficiently attenuates Alzheimer-like tau hyperphosphorylation. Although the exact mechanism is still not fully understood, a direct regulatory influence of melatonin on the activities of protein kinases and protein phosphatases is proposed. Additionally, melatonin also plays a role in protecting cholinergic neurons and in anti-inflammation. Here, the neuroprotective effects of melatonin and the underlying mechanisms by which it exerts its effects are reviewed. The capacity of melatonin to prevent or ameliorate tau and Aβ pathology further enhances its potential in the prevention or treatment of AD.
Wu YH, Swaab DF . The human pineal gland and melatonin in aging and Alzheimer's disease. J Pineal Res 2005; 38: 145–52.
Wu YH, Feenstra MG, Zhou JN, Liu RY, Torano JS, van Kan HJ, et al. Molecular changes underlying reduced pineal melatonin levels in Alzheimer disease: alterations in preclinical and clinical stages. J Clin Endocrinol Metab 2003; 88: 5898–906.
Ferrari E, Arcaini A, Gornati R, Pelanconi L, Cravello L, Fioravanti M, et al. Pineal and pituitary-adrenocortical function in physiological aging and in senile dementia. Exp Gerontol 2000; 35: 1239–50.
Ohashi Y, Okamoto N, Uchida K, Iyo M, Mori N, Morita Y . Daily rhythm of serum melatonin levels and effect of light exposure in patients with dementia of the Alzheimer's type. Biol Psychiatry 1999; 45: 1646–52.
Liu RY, Zhou JN, van Heerikhuize J, Hofman MA, Swaab DF . Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer's disease, and apolipoprotein E-epsilon4/4 genotype. J Clin Endocrinol Metab 1999; 84: 323–7.
Zhou JN, Liu RY, Kamphorst W, Hofman MA, Swaab DF . Early neuropathological Alzheimer's changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels. J Pineal Res 2003; 35: 125–30.
Rousseau A, Petren S, Plannthin J, Eklundh T, Nordin C . Serum and cerebrospinal fluid concentrations of melatonin: a pilot study in healthy male volunteers. J Neural Transm 1999; 106: 883–8.
Friedland RP, Luxenberg JS, Koss E . A quantitative study of intracranial calcification in dementia of the Alzheimer type. Int Psychogeriatr 1990; 2: 36–43.
Cohen-Mansfield J, Garfinkel D, Lipson S . Melatonin for treatment of sundowning in elderly persons with dementia: a preliminary study. Arch Gerontol Geriatr 2000; 31: 65–76.
Brusco LI, Marquez M, Cardinali DP . Melatonin treatment stabilizes chronobiologic and cognitive symptoms in Alzheimer's disease. Neuro Endocrinol Lett 2000; 21: 39–42.
Brusco LI, Marquez M, Cardinali DP . Monozygotic twins with Alzheimer's disease treated with melatonin: case report. J Pineal Res 1998; 25: 260–63.
Cardinali DP, Brusco LI, Lloret SP, Furio AM . Melatonin in sleep disorders and jet-lag. Neuro Endocrinol Lett 2002; 23 Suppl 1: 9–13.
Cardinali DP, Brusco LI, Liberczuk C, Furio AM . The use of melatonin in Alzheimer's disease. Neuro Endocrinol Lett 2002; 23 Suppl 1: 20–2.
Karasek M, Reiter RJ, Cardinali DP, Pawlikowski M . Future of melatonin as a therapeutic agent. Neuroendocrinol Lett 2002; 23 Suppl 1: 118–21.
Singer C, Tractenberg RE, Kaye J, Schafer K, Gamst A, Grundman M, et al. Alzheimer's disease cooperative study. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. Sleep 2003; 26: 893–90.
Nagtegaal J, Kerkhof GA, Smits MG, van der Meer YG, Fischer-Steenvoorden MGJ . Melatonin: a survey of suspected adverse drug reactions. In: Beersma DGM, Coenen AML editors Sleep-wake research in the Netherlands, vol 7; 1996; p 115–8.
Avery D, Lenz M, Landis C . Guidelines for prescribing melatonin. Ann Med 1998; 30: 122–30.
Pacchierottio C, Iapichino S, Bossini L, Pieraccini F, Castrogiovanni P . Melatonin in psychiatric disorders: a review on the melatonin involvement in psychiatry. Front Neuroendocrinol 2001; 22: 18–32.
Selkoe DJ . Alzheimer's disease is a synaptic failure. Science 2002; 298: 789–91.
Eckert A, Keil U, Marques CA, Bonert A, Frey C, Schussel K, et al. Mitochondrial dysfunction, apoptotic cell death, and Alzheimer's disease. Biochem Pharmacol 2003; 66: 1627–34.
Selkoe DJ . Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. Nat Cell Biol 2004; 6: 1054–61.
Saragoni L, Hernandez P, Maccioni RB . Differential association of tau with subsets of microtubules containing posttranslationally-modified tubulin variants in neuroblastoma cells. Neurochem Res 2000; 25: 59–70.
Brion JP, Anderton BH, Authelet M, Dayanandan R, Leroy K, Lovestone S, et al. Neurofibrillary tangles and tau phosphorylation. Biochem Soc Symp 2001; 67: 81–8.
Billingsley ML, Kincaid RL . Regulated phosphorylation and de-phosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration. Biochem J 1997; 323: 577–91.
Braak E, Braak H, Mandelkow EM . A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads. Acta Neuropathol (Berl) 1994; 87: 554–67.
Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM . Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem 1986; 261: 6084–9.
Lee VM, Balin BJ, Otvos L Jr, Trojanowski JQ . A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. Science 1991; 251: 675–8.
Bordt SL, McKeon RM, Li PK, Witt-Enderby PA, Melan MA . N1E-115 mouse neuroblastoma cells express MT1 melatonin receptors and produce neurites in response to melatonin. Biochim Biophys Acta 2001; 1499: 257–64.
Witt-Enderby PA, MacKenzie RS, McKeon RM, Carroll EA, Bordt SL, Melan MA . Melatonin induction of filamentous structures in non-neuronal cells that is dependent on expression of the human mt1 melatonin receptor. Cell Motil Cytoskeleton 2000; 46: 28–42.
Benitez-King G, Tunez I, Bellon A, Ortiz GG, Anton-Tay F . Melatonin prevents cytoskeletal alterations and oxidative stress induced by okadaic acid in N1E-115 cells. Exp Neurol 2003; 182: 151–9.
Benitez-King G . PKC activation by melatonin modulates vimentin intermediate filament organization in N1E-115 cells. J Pineal Res 2000; 29: 8–14.
Benitez-King G, Hernandez ME, Tovar R, Ramirez G . Melatonin activates PKC-alpha but not PKC-epsilon in N1E-115 cells. Neurochem Int 2001; 39: 95–102.
Eidenmuller J, Fath T, Hellwig A, Reed J, Sontag E, Brandt R . Structural and functional implications of tau hyperphosphorylation: information from phosphorylation-mimicking mutated tau proteins. Biochemistry 2000; 39: 13166–75.
Avila J . Tau aggregation into fibrillar polymers: taupathies. FEBS Lett 2000; 476: 82–92.
Gong CX, Liu F, Grundke-Iqbal I, Iqbal K . Post-translational modifications of tau protein in Alzheimer's disease. J Neural Transm 2005; 112: 813–38.
Deng YQ, Xu GG, Duan P, Zhang Q, Wang JZ . Effects of melatonin on wortmannin-induced tau hyperphosphorylation. Acta Pharmacol Sin 2005; 26: 519–26.
Li XC, Wang ZF, Zhang JX, Wang Q, Wang JZ . Effect of melatonin on calyculin A-induced tau hyperphosphorylation. Eur J Pharmacol 2005; 510: 25–30.
Li SP, Deng YQ, Wang XC, Wang YP, Wang JZ . Melatonin protects SH-SY5Y neuroblastoma cells from calyculin A-induced neurofilament impairment and neurotoxicity. J Pineal Res 2004; 36: 186–191.
Wang YP, Li XT, Liu SJ, Zhou XW, Wang XC, Wang JZ . Melatonin ameliorated okadaic-acid induced Alzheimer-like lesions. Acta Pharmacol Sin 2004; 25: 276–80.
Liu SJ, Wang JZ . Alzheimer-like tau phosphorylation induced by wortmannin in vivo and its attenuation by melatonin. Acta Pharmacol Sin 2002; 23: 183–7.
Wang DL, Ling ZQ, Cao FY, Zhu LQ, Wang JZ . Melatonin attenuates isoproterenol-induced protein kinase A overactivation and tau hyperphosphorylation in rat brain. J Pineal Res 2004; 37: 11–16.
Wang XC, Zhang J, Yu X, Han L, Zhou ZT, Zhang Y, et al. Prevention of isoproterenol-induced tau hyperphosphorylation by melatonin in the rat. Acta Physiol Sin 2005; 57: 7–12.
Zhu LQ, Wang SH, Ling ZQ, Wang DL, Wang JZ . Effect of inhibiting melatonin biosynthesis on spatial memory retention and tau phosphorylation in rat. J Pineal Res 2004; 37: 71–7.
Gong CX, Shaikh S, Wang JZ, Zaidi T, Grundke-Iqbal I, Iqbal K . Phosphatase activity toward abnormally phosphorylated tau: decrease in Alzheimer disease brain. J Neurochem 1995; 65: 732–8.
Reiter RJ, Acuna-Castroviejo D, Tan DX, Burkhardt S . Free radical-mediated molecular damage: mechanisms for the protective actions of melatonin in the central nervous system. Ann NY Acad Sci 2001; 939: 200–15.
Zhu X, Rottkamp CA, Boux H, Takeda A, Perry G, Smith MA . Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease. J Neuropathol Exp Neurol 2000; 59: 880–8.
Gomez-Ramos A, Diaz-Nido J, Smith MA, Perry G, Avila J . Effect of the lipid peroxidation product acrolein on tau phosphorylation in neural cells. J Neurosci Res 2003; 71: 863–70.
Lovell MA, Xiong S, Xie C, Davies P, Markesbery WR . Induction of hyperphosphorylated tau in primary rat cortical neuron cultures mediated by oxidative stress and glycogen synthase ki-nase-3. J Alzheimers Dis 2004; 6: 659–71.
Schuster C, Williams LM, Morris A, Morgan PJ, Barrett P . The human MT1 melatonin receptor stimulates cAMP production in the human neuroblastoma cell line SH-SY5Y cells via a calcium-calmodulin signal transduction pathway. J Neuroendocrinol 2005; 17: 170–8.
Peschke E, Muhlbauer E, Musshoff U, Csernus VJ, Chankiewitz E, Peschke D . Receptor (MT(1)) mediated influence of melatonin on cAMP concentration and insulin secretion of rat insulinoma cells INS-1. J Pineal Res 2002; 33: 63–71.
Rivera-Bermudez MA, Gerdin MJ, Earnest DJ, Dubocovich ML . Regulation of basal rhythmicity in protein kinase C activity by melatonin in immortalized rat suprachiasmatic nucleus cells. Neurosci Lett 2003; 346: 37–40.
Benitez-King G, Rios A, Martinez A, Anton-Tay F . In vitro inhibition of Ca2+/calmodulin-dependent kinase II activity by melatonin. Biochim Biophys Acta 1996; 1290: 191–6.
Chan AS, Lai FP, Lo RK, Voyno-Yasenetskaya TA, Stanbridge EJ, Wong YH . Melatonin mt1 and MT2 receptors stimulate c-Jun N-terminal kinase via pertussis toxin-sensitive and -insensitive G proteins. Cell Signal 2002; 14: 249–57.
Kilic U, Kilic E, Reiter RJ, Bassetti CL, Hermann DM . Signal transduction pathways involved in melatonin-induced neuroprotection after focal cerebral ischemia in mice. J Pineal Res 2005; 38: 67–71.
Selkoe DJ . The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol 1998; 8: 447–53.
Lahiri DK . Melatonin affects the metabolism of the beta-amyloid precursor protein in different cell types. J Pineal Res 1999; 26: 137–46.
Song W, Lahiri DK . Melatonin alters the metabolism of the beta-amyloid precursor protein in the neuroendocrine cell line PC12. J Mol Neurosci 1997; 9: 75–92.
Zhang YC, Wang ZF, Wang Q, Wang YP, Wang JZ . Melatonin attenuates overproduction of β-amyloid-induced inhibition in expression of neurofilament protein. Acta Pharmacol Sin 2004; 25: 447–51.
Matsubara E, Bryant-Thomas T, Pacheco Quinto J, Henry TL, Poeggeler B, Herbert D, et al. Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. J Neurochem 2003; 85: 1101–8.
Lahiri DK, Chen D, Ge YW, Bondy SC, Sharman EH . Dietary supplementation with melatonin reduces levels of amyloid beta-peptides in the murine cerebral cortex. J Pineal Res 2004; 36: 224–31.
Olivieri G, Hess C, Savaskan E, Ly C, Meier F, Baysang G, et al. Melatonin protects SHSY5Y neuroblastoma cells from cobalt-induced oxidative stress, neurotoxicity and increased beta-amyloid secretion. J Pineal Res 2001; 31: 320–5.
Quinn J, Kulhanek D, Nowlin J, Jones R, Pratico D, Rokach J, et al. Chronic melatonin therapy fails to alter amyloid burden or oxidative damage in old Tg2576 mice: implications for clinical trials. Brain Res 2005; 1037: 209–13.
Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996; 274: 99–102.
Fisher A, Pittel Z, Haring R, Bar-Ner N, Kliger-Spatz M, Natan N, et al. M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy. J Mol Neurosci 2003: 20; 349–56.
Su Y, Ryder J, Li B, Wu X, Fox N, Solenberg P, et al. Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing. Biochemistry 2004; 43: 6899–908.
Ryder J, Su Y, Liu F, Li B, Zhou Y, Ni B . Divergent roles of GSK3 and CDK5 in APP processing. Biochem Biophys Res Commun 2003; 312: 922–9.
Phiel CJ, Wilson CA, Lee VM, Klein PS . GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 2003; 423: 435–9.
Tesco G, Tanzi RE . GSsK3 beta forms a tetrameric complex with endogenous PS1–CTF/NTF and beta-catenin. Effects of the D257/D385A and FAD-linked mutations. Ann NY Acad Sci 2000; 920: 227–32.
Takashima A, Murayama M, Murayama O, Kohno T, Honda T, Yasutake K, et al. Presenilin 1 associates with glycogen synthase kinase-3beta and its substrate tau. Proc Natl Acad Sci USA 1998; 95: 9637–41.
Simmons LK, May PC, Tomaselli KJ, Rydel RE, Fuson KS, Brigham EF, et al. Secondary structure of amyloid beta peptide correlates with neurotoxic activity in vivo. Mol Pharmacol 1994; 45: 373–9.
Soto C, Castano EM . The conformation of Alzheimer's beta peptide determines the rate of amyloid formation and its resistance to proteolysis. Biochem J 1996; 314: 701–7.
Poeggeler B, Miravalle L, Zagorski MG, Wisniewski T, Chyan YJ, Zhang Y, et al. Melatonin reverses the profibrillogenic activity of apolipoprotein E4 on the Alzheimer amyloid Abeta peptide. Biochemistry 2001; 40: 14995–5001.
Skribanek Z, Balaspiri L, Mak M . Interaction between synthetic amyloid-peptide (1–40) and its aggregation inhibitors studied by electrospray ionization mass spectrometry. J Mass Spectrom 2001; 36: 1226–9.
Pappolla M, Bozner P, Soto C, Shao H, Robakisi NK, Zagorski M, et al. Inhibition of Alzheimer β-fibrillogenesis by melatonin. J Biol Chem 1998; 273: 7185–8.
Huang TH, Fraser PE, Chakrabartty A . Fibrillogenesis of Alzheimer Abeta peptides studied by fluorescence energy transfer. J Mol Biol 1997; 269: 214–24.
Fraser PE, Nguyen JT, Surewicz WK, Kirschner DA . pH-dependent structural transitions of Alzheimer amyloid peptides. Biophys J 1991; 60: 1190–201.
Bieschke J, Zhang Q, Powers ET, Lerner RA, Kelly JW . Oxidative metabolites accelerate Alzheimer's amyloidogenesis by a two-step mechanism, eliminating the requirement for nucleation. Biochemistry 2005; 44: 4977–83.
Feng Z, Zhang JT . Protective effect of melatonin on beta-amyloid-induced apoptosis in rat astroglioma C6 cells and its mechanism. Free Radic Biol Med 2004; 37: 1790–801.
Zatta P, Tognon G, Carampin P . Melatonin prevents free radical formation due to the interaction between beta-amyloid peptides and metal ions [Al(III), Zn(II), Cu(II), Mn(II), Fe(II)]. J Pineal Res 2003; 35: 98–103.
Feng Z, Chang Y, Cheng Y, Zhang BL, Qu ZW, Qin C, et al. Melatonin alleviates behavioral deficits associated with apoptosis and cholinergic system dysfunction in the APP 695 transgenic mouse model of Alzheimer's disease. J Pineal Res 2004; 37: 129–36.
Shen YX, Xu SY, Wei W, Sun XX, Liu LH, Yang J, et al. The protective effects of melatonin from oxidative damage induced by amyloid beta-peptide 25–35 in middle-aged rats. J Pineal Res 2002; 32: 85–9.
Rosales-Corral S, Tan DX, Reiter RJ, Valdivia-Velazquez M, Martinez-Barboza G, Acosta-Martinez JP, et al. Orally administered melatonin reduces oxidative stress and proinflamma-tory cytokines induced by amyloid-beta peptide in rat brain: a comparative, in vivo study versus vitamin C and E. J Pineal Res 2003; 35: 80–4.
Kar S, Slowikowski SP, Westaway D, Mount HT . Interaction between β-amyloid and central cholinergic neurons: implications for Alzheimer's disease. J Psychiatry Neurosci 2004; 29: 427–41.
Guermonprez L, Ducrocq C, Gaudry-Talarmain YM . Inhibition of acetylcholine synthesis and tyrosine nitration induced by peroxynitrite are differentially prevented by antioxidants. Mol Pharmacol 2001; 60: 838–46.
Feng Z, Cheng Y, Zhang JT . Long-term effects of melatonin or 17 beta-estradiol on improving spatial memory performance in cognitively impaired, ovariectomized adult rats. J Pineal Res 2004; 37: 198–206.
Mitchell CK, Redburn DA . Melatonin inhibits ACh release from rabbit retina. Vis Neurosci 1991; 7: 479–86.
Stuchbury G, Munch G . Alzheimer's associated inflammation, potential drug targets and future therapies. J Neural Transm 2005; 112: 429–53.
Tuppo EE, Arias HR . The role of inflammation in Alzheimer's disease. Int J Biochem Cell Biol 2005; 37: 289–305.
Ho GJ, Drego R, Hakimian E, Masliah E . Mechanisms of cell signaling and inflammation in Alzheimer's disease. Curr Drug Targets Inflamm Allergy 2005; 4: 247–56.
Chung SY, Han SH . Melatonin attenuates kainic acid-induced hippocampal neurodegeneration and oxidative stress through microglial inhibition. J Pineal Res 2003; 34: 95–102.
Pei Z, Cheung RT . Pretreatment with melatonin exerts anti-inflammatory effects against ischemia/reperfusion injury in a rat middle cerebral artery occlusion stroke model. J Pineal Res 2004; 37: 85–91.
Beni SM, Kohen R, Reiter RJ, Tan DX, Shohami E . Melatonin-induced neuroprotection after closed head injury is associated with increased brain antioxidants and attenuated late-phase activation of NF-kappaB and AP-1. FASEB J 2004; 18: 149–151.
Sasaki M, Jordan P, Joh T, Itoh M, Jenkins M, Pavlick K, et al. Melatonin reduces TNF-α induced expression of MAdCAM-1 via inhibition of NF-kappaB. BMC Gastroenterol 2002; 2: 9.
Noble W, Planel E, Zehr C, Olm V, Meyerson J, Suleman F, et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA 2005; 102: 6990–5.
Savaskan E, Olivieri G, Meier F, Brydon L, Jockers R, Ravid R, et al. Increased melatonin 1α-receptor immunoreactivity in the hippocampus of Alzheimer's disease patients. J Pineal Res 2002; 32: 59–62.
Savaskan E, Ayoub MA, Ravid R, Angeloni D, Fraschini F, Meier F, et al. Reduced hippocampal MT2 melatonin receptor expression in Alzheimer's disease. J Pineal Res 2005; 38: 10–6.
Project partially supported by grants from the National Natural Science Foundation of China (No 30430270, 30400068, 30472030, and 30328007) and from National Major Grants for Basic Research (No G1999054007 and 2006CB500703).
About this article
Cite this article
Wang, Jz., Wang, Zf. Role of melatonin in Alzheimer-like neurodegeneration. Acta Pharmacol Sin 27, 41–49 (2006). https://doi.org/10.1111/j.1745-7254.2006.00260.x
- Alzheimer disease
- tau, beta amyloid
This article is cited by
Nature Reviews Neurology (2022)
Nuclear Science and Techniques (2022)
The potential neuroprotective effect of allicin and melatonin in acrylamide-induced brain damage in rats
Environmental Science and Pollution Research (2021)
Melatonin alleviates intervertebral disc degeneration by disrupting the IL-1β/NF-κB-NLRP3 inflammasome positive feedback loop
Bone Research (2020)